Skip to main content

Commodore Capital LP

SEC CIK
0001831942
Latest filing
Aug 14, 2026

Holdings in Q4 2022

Holdings as of Dec 31, 2022, filed Feb 14, 2023. Long positions only; changes compare share counts with Q3 2022.

Institution overview
Positions
35
+5 vs. Q3 2022
Portfolio value
$663.5M
+$41.7M (+6.7%) vs. Q3 2022
Filed
Feb 14, 2023
SEC
Holdings of Commodore Capital LP in Q4 2022
SecurityClassSharesValue% of portfolioShare changeActionHistory
XENEXenon Pharmaceuticals Inc.COM1,659,111$65.4M9.9%+64,179+4.0%AddedHistory
VRDNViridian Therapeutics, Inc.COM2,020,166$59.0M8.9%−676,174−25.1%ReducedHistory
COGTCogent Biosciences, Inc.COM4,319,940$49.9M7.5%00.0%UnchangedHistory
Bellus Health Inc New07987C204COM NEW5,303,557$43.6M6.6%+175,000+3.4%Added–
MRUSMerus N.V.COM2,732,567$42.3M6.4%+116,805+4.5%AddedHistory
CBAYCymaBay Therapeutics, Inc.COM5,738,500$36.0M5.4%00.0%UnchangedHistory
ACRSAclaris Therapeutics, Inc.COM1,880,286$29.6M4.5%−530,336−22.0%ReducedHistory
AKROAkero Therapeutics, Inc.COM537,076$29.4M4.4%−206,396−27.8%ReducedHistory
NUVLNuvalent, Inc.COM913,621$27.2M4.1%+913,621NewHistory
CLDXCelldex Therapeutics, Inc.COM NEW495,823$22.1M3.3%−42,989−8.0%ReducedHistory
IMVTImmunovant, Inc.COM1,150,505$20.4M3.1%+1,150,505NewHistory
ARWRArrowhead Pharmaceuticals, Inc.COM462,111$18.7M2.8%+58,033+14.4%AddedHistory
CELCCelcuity Inc.COM1,327,952$18.6M2.8%+407,488+44.3%AddedHistory
ACLXArcellx, Inc.COMMON STOCK591,437$18.3M2.8%+591,437NewHistory
SNDXSyndax Pharmaceuticals IncCOM688,445$17.5M2.6%−49,665−6.7%ReducedHistory
DAWNDay One Biopharmaceuticals, Inc.Stock739,661$15.9M2.4%00.0%UnchangedHistory
RXDXPrometheus Biosciences, Inc.COM127,156$14.0M2.1%+127,156NewHistory
ALLKAllakos Inc.COM1,643,500$13.8M2.1%00.0%UnchangedHistory
KURAKura Oncology, Inc.COM1,099,407$13.6M2.1%+200,000+22.2%AddedHistory
FDMT4D Molecular Therapeutics, Inc.COM598,385$13.3M2.0%+598,385NewHistory
Avidity Biosciences, Inc.05370A108COM590,705$13.1M2.0%+590,705New–
ENTAEnanta Pharmaceuticals IncCOM223,494$10.4M1.6%+120,000+115.9%AddedHistory
ELVNEnliven Therapeutics, Inc.COM2,494,794$10.2M1.5%+2,494,794NewHistory
ALPNAlpine Immune Sciences, Inc.COM1,325,000$9.74M1.5%00.0%UnchangedHistory
ETNB89bio, Inc.COM758,244$9.65M1.5%+758,244NewHistory
CABACabaletta Bio, Inc.COM1,010,359$9.35M1.4%+1,010,359NewHistory
PCVXVaxcyte, Inc.COM173,481$8.32M1.3%+173,481NewHistory
KPTIKaryopharm Therapeutics Inc.COM1,935,609$6.58M1.0%00.0%UnchangedHistory
THRDThird Harmonic Bio, Inc.COM993,294$4.27M0.6%−25,275−2.5%ReducedHistory
LRMRLarimar Therapeutics, Inc.COM750,000$3.10M0.5%00.0%UnchangedHistory
ABOSAcumen Pharmaceuticals, Inc.COM498,315$2.69M0.4%−601,685−54.7%ReducedHistory
IMUXImmunic, Inc.COM1,800,000$2.52M0.4%+906,987+101.6%AddedHistory
RZLTRezolute, Inc.COM NEW1,210,000$2.50M0.4%00.0%UnchangedHistory
KALVKalVista Pharmaceuticals, Inc.COM312,553$2.11M0.3%00.0%UnchangedHistory
DBVTDBV Technologies S.A.SPONSORED ADR92,687$142.0K<0.1%+92,687NewHistory

Sold out since Q3 2022 (6)

Positions held at the end of Q3 2022 that are gone from this filing.

Positions of Commodore Capital LP sold out since Q3 2022
SecurityClassShares in Q3 2022Value in Q3 2022% of portfolio in Q3 2022History
CYTKCytokinetics IncCOM NEW893,646$43.3M7.0%History
STSASatsuma Pharmaceuticals, Inc.COM3,711,286$22.3M3.6%History
TCDATricida, Inc.COM1,975,403$20.7M3.3%History
ESPREsperion Therapeutics, Inc.COM467,468$3.13M0.5%History
BCLS Acquisition CorpG0904B105COM CL A250,000$2.50M0.4%–
TERNTerns Pharmaceuticals, Inc.COM205,870$1.21M0.2%History